Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (193)	1/14/2005 3:22:00 PM
From: fred hayes	Respond to of 802

peg-3 followup: I didn't read the link in last msg very carefully. Looks like patent was issued May 18, 2004...

To: fred hayes who wrote (193)	1/14/2005 3:30:51 PM
From: tuck	Read Replies (1) \| Respond to of 802

Yeah, I found that, it's one of the links at the bottom here: Message 20942717 I can't confirm anything since then, either. No other assignee yet, so presumably Columbia still owns it. I was wondering if this was covered by any agreement between INGN and Columbia, since INGN's been linked with Fisher's lab for a number of years. So I was hoping INGN had first dibs on this, as it seems pretty interesting. A look in the S1/A suggests not (after all, Fisher does have other projects, PEG-Prom is apparently one of them). The original agreement covered only MDA-7 for gene therapy, as far as I can tell, and was between Columbia and a company that Corixa bought. Corixa then licensed out that IP to INGN. Anyhow, not of immediate relevance. How about some H&N cancer results or sumthin? Cheers, Tuck